{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:05:36Z","timestamp":1758125136043},"reference-count":3,"publisher":"Colegio Mexicano de Inmunologia Clinica y Alergia, A. C.","issue":"3","license":[{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Alerg Mex"],"abstract":"<jats:p>Antecedentes: El asma es una enfermedad inflamatoria cr\u00f3nica de v\u00edas respiratorias, provocada por c\u00e9lulas y mediadores inflamatorios, asociado a disfunci\u00f3n del m\u00fasculo liso, provocando obstrucci\u00f3n variable del flujo aereo. Con mecanismos inmunoinflamatorios tipo 2 altos, bajos y mixtos (endotipos). Asma grave es aquella que requiere paso 4 o 5 de tratamiento (GINA 2023). El fenotipo TH2 Alto, no alergico con eosinofilia y FENO, es el segundo m\u00e1s com\u00fan. Afecta a 300 millones de personas alrededor del mundo.\nObjetivo: Describir biomarcadores de asma, posterior al uso de antiinterleucina 5, Benralizumab, en adultos con asma grave.\nM\u00e9todos: Reporte de casos, estudio descriptivo. Se incluyeron pacientes con asma grave eosinofilica y rinosinusitis cr\u00f3nica poliposica en tratamiento con anti-IL5, evaluando biomarcadores inflamatorios\nResultados: En 8 pacientes se midieron eosin\u00f3filos s\u00e9ricos, FENO, ACT, espirometr\u00eda y exacerbaciones al inicio y 6 meses despu\u00e9s del tratamiento. El FEV1-FVC fue 51% con mejor\u00eda hasta 95% despu\u00e9s. 5 pacientes ten\u00edan FENO &gt;45 ppm posteriormente solo 3 continuron inflamados. Eosinofilia 150 c\u00e9lulas y posteriormente solo 1 paciente persisti\u00f3 con eosinofilia 200 c\u00e9lulas. ACT inicial &lt; 19 en 7 pacientes ACT final &gt;19 en 7 pacientes. Exacerbaciones 8 pacientes con 2 o m\u00e1s exacerbaciones posteriormente solo 1 paciente present\u00f3 exacerbaci\u00f3n.\nConclusi\u00f3n: El uso de antiinterleucina 5 (Benralizumab) si disminuye marcadores inflamatorios, mejora el control y n\u00famero de exacerbaciones a corto plazo. Los anticuerpos monoclonales (Anti IL-5), si mejoran biomarcadores inflamatorios si se toman en cuenta caracteristicas cl\u00ednicas y biomarcadores inflamatorios favorece adecuado control de asma.<\/jats:p>","DOI":"10.29262\/ram.v70i3.1269","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T08:02:24Z","timestamp":1694505744000},"page":"199","source":"Crossref","is-referenced-by-count":1,"title":["Control de asma grave predominantemente eosinof\u00edlica con el uso de anti IL-5"],"prefix":"10.29262","volume":"70","author":[{"given":"Martha Alicia  Ruiz Pe\u00f1aloza","family":"Ruiz Pe\u00f1aloza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Jes\u00fas","family":"L\u00f3pez Tiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zayra Estefan\u00eda","family":"Ort\u00edz Morte\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Garc\u00eda Rosas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11808","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"54300","unstructured":"Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab - PubMed. PubMed. Accedido el 30 de mayo de 2023. https:\/\/pubmed.ncbi.nlm.nih.gov\/35287231\/"},{"key":"54301","unstructured":"2. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years - PubMed. PubMed. Accedido el 30 de mayo de 2023. https:\/\/pubmed.ncbi.nlm.nih.gov\/34487870\/"},{"key":"54302","unstructured":"3. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab - PubMed. PubMed. Accedido el 30 de mayo de 2023. https:\/\/pubmed.ncbi.nlm.nih.gov\/32242310\/"}],"container-title":["Revista Alergia M\u00e9xico"],"original-title":[],"link":[{"URL":"https:\/\/www.revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1269\/2081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.revistaalergia.mx\/ojs\/index.php\/ram\/article\/download\/1269\/2081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T08:02:30Z","timestamp":1694505750000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.revistaalergia.mx\/ojs\/index.php\/ram\/article\/view\/1269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,21]]},"references-count":3,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,11]]}},"URL":"https:\/\/doi.org\/10.29262\/ram.v70i3.1269","relation":{},"ISSN":["2448-9190","0002-5151"],"issn-type":[{"value":"2448-9190","type":"electronic"},{"value":"0002-5151","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,21]]}}}